Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

U090 - Controversies in Management and Treatment of Cutaneous Lupus and Dermatomyositis Patient

Monday, February 19; 4:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Identify controversies over management and treatment of patients with cutaneous lupus and dermatomyositis
  • Summarize literature with differing views on specific topics on management and treatment of patients with cutaneous lupus and dermatomyositis
  • Treat and manage recommendations based on best practice guidelines


The purpose of this focus session is to identify and discuss management and treatment controversies of cutaneous lupus and dermatomyositis patients. The intended audience is practicing medical dermatologists. Topics/questions to be discussed include: 1) How does one monitor cutaneous lupus patients for progression to SLE? 2) Does smoking negatively affect the therapeutic benefit of anti-malarials? 3) What are the preferred screening modalities for cancers and interstitial lung disease in dermatomyositis patients? 4) Are myositis antibody profiles helpful in the diagnosis and management of dermatomyositis patients?


  • Chong, Benjamin F., MD, MSc: Biogen – I(Grants/Research Funding); Celgene Corporation – A(H); Daavlin Company – I(Grants/Research Funding); Pfizer Inc. – I(Grants/Research Funding); Viela Bio – C(H);
  • Werth, Victoria P., MD: AstraZeneca – A(H); Biogen – C(H), I(Grants/Research Funding); BMS – C(H); Celgene Corporation – C(H), I(Grants/Research Funding); CSL – C(H); Genentech, Inc. – C(H); Gilead Sciences – C(H), I(Grants/Research Funding); Idera Pharmaceuticals, Inc. – C(H); Immune Pharmaceuticals – C(H); Immunotherapeutics – C(H); Janssen Pharmaceuticals, Inc – C(H), I(Grants/Research Funding); Lilly ICOS LLC – C(H); Lupus Foundation of America – C(H); Medimmune – C(H); Neovacs – C(H); Octapharma – C(H); Pfizer Inc. – C(H), I(Grants/Research Funding); Principia Biopharma Inc. – C(H); Resolve Therapeutics – C(H); Roche Laboratories – C(H); Stiefel a GSK company – C(H); Syntimmune, Inc. – C(H), I(Grants/Research Funding); UV Therapeutics – A(ST);
Event Details
  • Date
    Monday, February 19
  • Time
    4:30 PM - 5:30 PM
  • Location
    Room 2
  • CME Credits
  • Type
  • Benjamin F. Chong, MD, MSc, FAAD - Handout
  • Victoria P. Werth, MD, FAAD